In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Surprise Winner in MGI Auction

Executive Summary

Everyone knew that MGI Pharma was up for sale, but few expected mid-cap Japanese firm Eisai to emerge victorious. Eisai pushed its offer up to $41-per-share, all cash, even though there was only one other, non-definitive, offer on the table. The $3.3 billion deal nabs Eisai two records: the largest foreign acquisition by any Japanese pharma, and the year's largest specialty pharma purchase.

You may also be interested in...

Flush With Cash, Tesaro Advances Rolapitant Toward NDA

Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.

Tesaro Scores $101M In A Second Round Of Funding

The Boston biotech has plans to use its Series B financing to fund its current research, as well as invest in other assets to flesh out its pipeline.

Best of the Blog: IN VIVO, June 2008

Best of the Blog is a monthly column highlighting the best of our free online content at In June and early July, Windhover's editorial staff posted more than seventy articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights included our very first "fantasy dealmaking" post as well as our take on PhRMA's new marketing regulations. Here are a few of our favorite blog posts for stories not covered elsewhere in this month's IN VIVO.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts